NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Innate Pharma SA IPHA
9 fiscal years on record · EUR · FY2025 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
EUR 9.0M
Revenue, FY2025 · full 9-year series below
Revenue €M
Net income €M
FY2025 · Revenue 9.0 · Net income -49.2
40.0M80.0M-25.0M-50.0M
2017202020232025
Compound annual growth
Revenue compounded at −33.6% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−546 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -599.8% · Net -546.1%
-200%-400%
201720212025
ROE
FY2024 · ROE -162.9%
-50%-100%-150%
201720212025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on assets-56.6%
Return on capital employed-103.7%
Return on equity has no reading this year — return on capital employed, just below, still does: -104%.
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · EUR
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue €B | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 |
| Operating income €B | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| EBITDA €B | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Income tax €B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 |
| Net income €B | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | 0.0 | −0.0 |
| Free cash flow €B | −0.1 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | 0.0 | −0.0 | −0.1 |
| EPS, diluted € | −0.55 | −0.61 | −0.09 | −0.73 | −0.66 | −0.81 | −0.31 | 0.05 | −0.89 |
| Dividend / sh € | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — |
| ROE % | — | −162.9 | −14.3 | −71.9 | −40.1 | −34.3 | −10.8 | 2.3 | −48.7 |
| Shares out B | ◌ | ◌ | ◌ | 0.08 | ◌ | ◌ | ◌ | ◌ | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 36 reconciliationsAUDITED
Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code I0
Fiscal year endsDecember 31
Data on record since2017